Testing effectiveness (Phase 2)Study completedNCT06322342
What this trial is testing
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Who this might be right for
Central Nervous System (CNS) LesionsBrain MetastasesBrain Neoplasms+22 more
Reveal Pharmaceuticals Inc. 18